IDEXX beats Q2, raises 2026 outlook, buys AI vet software
Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.